Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: Effect of eplerenone

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 1, 2006, Pages 31-39

  Nebme, Johnny ^a   Mercier, Nathalie ^a   Labat, Carlos ^a   Benetos, Athanase ^a   Safar, Michel E ^b   Delcayre, Claude ^a   Lacolley, Patrick ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

Arteries; Elasticity; Hypertension; Pharmacology

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; EPLERENONE; FIBRONECTIN; MESSENGER RNA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY COMPLIANCE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEEDING; FIBROMUSCULAR DYSPLASIA; HEART MUSCLE FIBROSIS; HEART WEIGHT; HISTOPATHOLOGY; HORMONE ACTION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NORTHERN BLOTTING; PROTEIN DETERMINATION; RAT; RAT STRAIN; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; YOUNG MODULUS;

EID: 33745140192     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.004     Document Type: Article

References (36)

1. Brilla CG, Pick R, Tan LB et al. Remodelling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
2. Robert V, Van Thiem N, Cheav SI et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994;24:30-6.
3. Young M, Fullerton M, Dilley R et al. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93:2578-83.
4. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
5. Robert V, Silvestre JS, Charlemagne D et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995;26:971-8.
6. Lombes M, Oblin ME, Gasc JM et al. Immunohistochemical and biochemical evidence of a cardiovascular mineralocorticoid receptor. Circ Res 1992;71:503-10.
7. Takeda Y, Miyamori I, Yoneda T et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
8. Hatakeyama H, Miyamori I, Fujita T et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994;269:24316-20.
9. Weber KT, Brilla CG, Campbell SE et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993;88 (Suppl 1):107-24.
10. Silvestre JS, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
11. Lacolley P, Safar ME, Lucet B et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-7.
12. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats (SHRs). Arterioscler Thromb Vasc Biol 1997;17:1152-6.
13. Lacolley P, Labat C, Pujol A et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats - effects of eplerenone. Circulation 2002;106:2848-53.
14. Swynghedauw B, Besse S, Assayag P et al. Molecular and cellular biology of the senescent hypertrophied and failing heart. Am J Cardiol 1995;76:2D-7D.
15. Bezie Y, Lamazier J-M D, Laurent S et al. Fibronectine expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1998; 18:1027-34.
16. Robert V, Heymes C, Silvestre JS et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-6.
17. Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 2003;16:319-23.
18. Ramirez-Gil JF, Delcayre C, Robert V et al. In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. J Cardiovasc Pharmacol 1998;32:927-34.
19. Pitt B, Williams G, Remme W et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
20. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004;217:45-52.
21. Fraccarollo D, Galuppo P, Hildemann S et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-73.
22. Nishikimi T, Horio T, Sasaki T et al. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension 1997;30:1369-75.
23. Waldstein SS, Arcilla RA. Measurement of hepatic blood flow by clearance methods; a review and a theoretical basis for a new noncatheterization method. Am J Dig Dis 1958;3:137-58.
24. Weiss YA, Safar ME, Lehner JP et al. (+)-Propranolol clearance, an estimation of hepatic blood flow in man. Br J Clin Pharmacol 1978;5:457-60.
25. Gildner CD, Lerner AL, Hocking DC. Fibronectin matrix polymerization increases tensile strength of model tissue. Am J Physiol Heart Circ Physiol 2004;287:H46-H53.
26. Tsukamoto Y, Helsel WE, Wahl SM. Macrophage production of fibronectin, a chemoattractant for fibroblasts. J Immunol 1981;127:673-8.
27. Katayama K, Armendariz-Borunda J, Raghow R et al. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem 1993;268:9941-4.
28. Contard F, Koteliansky V, Marotte F et al. Specific alterations in the distribution of extracellular matrix components within rat myocardium during the development of pressure overload. Lab Invest 1991;64:65-75.
29. Nishizaka MK, Zaman MA, Green SA et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004;109:2857-61.
30. Garnier A, Bendall JK, Fuchs S et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004;110:1819-25.
31. Nichols WW, O'Rourke MF, Avolio AP et al. Effects of age on ventricular-vascular coupling. Am J Cardiol 1985;55:1179-84.
32. Safar ME, Cattan V, Lacolley P et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005;23:1159-66.
33. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-800.
34. Wojciechowska W, Staessen JA, Stolarz K et al. European Project on Genes in Hypertension (EPOGH) Investigators. Association of peripheral and central arterial wave reflections with the CYP11B2 -344C allele and sodium excretion. J Hypertens 2004;22:2311-19.
35. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
36. London GM, Pannier B, Guerin AP et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;90:2786-96.